Lupin Limited (LUPIN) share price and analysis
LUPIN last traded at ₹1,950.00 (-1.35%) on the NSE. Market cap ₹89,172 Cr (Mid cap), Pharma & Healthcare sector.
Overall rating: 6.0/10 (Average)
- Valuation: 8.6/10
- Profitability: 8.9/10
- Growth: 3.8/10
- Financial health: 8.2/10
- Price trend: 0.7/10
Long-term view: Good for long-term. More strengths than weaknesses for a multi-year hold. Trade bias (next few weeks): Strong short. Trend and momentum are clearly pointing down.
Strengths of LUPIN
- Valuation (P/E) (P/E 17.2 vs sector 41.1): Trades about 58% below its sector's median P/E, so it's cheaper than peers. Make sure growth isn't the reason.
- Return on equity (23.9%): Earns ₹24 profit for every ₹100 of shareholder capital, which is excellent capital efficiency.
- Debt / equity (0.26): Comfortable debt level.
- Free cash flow (4.5% FCF yield): Strong free cash flow relative to its market value.
- Net profit margin (16.9%): Healthy profit margins.
- Revenue growth (YoY) (+11.1%): Solid sales growth.
- Analyst target (₹2,310 (+18.5%)): 36 analysts' average target implies +18.5%, moderate upside.
- Volatility (1Y) (20% annualised): Low volatility. A relatively steady stock.
- Current ratio (1.84): Comfortable liquidity.
Weaknesses of LUPIN
- Long-term trend (-12.7% vs 200-DMA): Well below its 200-day average, in a long-term downtrend.
- Profit growth (YoY) (-22.1%): Profits are falling sharply.
- 50-DMA vs 200-DMA (-9.5% gap): 50-day average is below the 200-day (death-cross setup), so medium-term momentum is down.
- 6-month performance vs Nifty 50 (-14.3% vs +7.4%): Badly underperforming the Nifty 50.
- Momentum (RSI 14) (RSI 40): Bearish momentum. Sellers are in control.
- 52-week range (23% below high): Near its 52-week low, under persistent selling pressure.
Key numbers
| Number | Value | Assessment | Normal range |
|---|---|---|---|
| P/E (TTM) | 17.2 | Cheaper than peers | 37.0–49.3 (sector median 41.1) |
| Forward P/E | 20.0 | Profits expected to fall | below today's P/E (17.2) and near 41 |
| Price / book | 3.71 | Low | 6–12 (high ROE allows more) |
| EPS (TTM) | ₹113.48 | Profitable | above ₹0 |
| Return on equity | 23.9% | Strong | 15%+ (below 10% is weak) |
| Debt / equity | 0.26 | Low debt | below 1.0 (under 0.5 is great) |
| Net margin | 16.9% | Healthy | 10%+ (below 5% is thin) |
| Operating margin | 23.4% | Strong | 20%+ strong, below 10% thin |
| Revenue growth | +11.1% | Growing well | 10%+ a year (below 3% is weak) |
| Profit growth | -22.1% | Falling | 10%+ a year (falling is weak) |
| Dividend yield | 0.91% | Small payout | 1.5%+ (none is fine for growth firms) |
| Current ratio | 1.84 | Comfortable | 1.5+ (below 1 is tight) |
| 52W high | ₹2,529.50 | 23% below · far from the high | price in the top 40% of its 52-week range |
| 52W low | ₹1,892.90 | Price is 3% above it | |
| 50-DMA | ₹2,021.65 | Price 3.5% below | price above it = short-term uptrend |
| 200-DMA | ₹2,233.56 | Price 12.7% below | price above it = long-term uptrend |
| 1Y return | -2.0% | In line with Nifty 50 | Nifty 50 did −0.4% |
| Beta | 0.16 | Steadier than the market | 0.8–1.3 (1 = moves with market) |
| Promoter / insider | 47.0% | Moderate stake | 50%+ shows owner commitment |
| Institutions | 35.3% | Strong big-investor interest | 30%+ is strong |
| Analyst target | ₹2,310.11 | 18.5% upside · 36 analysts | 8%+ upside |
Questions about LUPIN
What is the share price of Lupin Limited (LUPIN) today?
LUPIN last traded at ₹1,950.00 (-1.35% on the day) on the NSE. Its 52-week range is ₹1,892.90 to ₹2,529.50. Prices are delayed and come from Yahoo Finance.
Is LUPIN a good stock for the long term?
StockLens rates LUPIN 6.0 out of 10 (Average) overall. Its long-term verdict is "Good for long-term": More strengths than weaknesses for a multi-year hold. Strengths: cheap vs peers, high ROE, low debt. Concerns: downtrend, falling profits, bearish moving averages.
Is LUPIN share overvalued?
LUPIN trades at a P/E of 17.2 against a Pharma & Healthcare median of 41.1, which StockLens rates as "Cheaper than peers". Its price-to-book ratio is 3.71.
Is LUPIN good for short-term trading?
The trade bias for the next few weeks is "Strong short": Trend and momentum are clearly pointing down. The price is 12.7% below its 200-day average and 14-day RSI is 40.
Which stocks are similar to LUPIN?
Similar Pharma & Healthcare stocks of comparable size include Max Healthcare, Aurobindo Pharma, Glenmark Pharmaceuticals, Cipla, Dr. Reddy's Laboratories. You can compare up to 4 of them side by side on StockLens.
About Lupin Limited
Lupin Limited, together with its subsidiaries, operates as a pharmaceutical company in India, the United States, and internationally. The company operates in two segments: Pharmaceuticals and Others. It produces, develops, and markets various branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs). The company also offers products in the therapeutic areas of cardiovascular, diabetology, asthama, pediatrics, central nervous system, gastro-intestinal, anti-infectives, anti-TB, cephalosporins, and nonsteroidal anti-inflammatory drug therapies. In addition, it provides chronic therapies, and hospital-based products; products for diabetes and iron supplements for anemia, and a Budesonide-Formoterol combination for asthma. Further, the company is involved in the provision of diagnostics services, and digital healthcare services; and neuro rehabilition business. It operates through network consisting of labs and collection centers. The company has a strategic collaboration with TB Alliance to support the clinical development and commercialization of Telacebec for the treatment of tuberculosis, leprosy, and buruli ulcer. The company was formerly known as Lupin Chemicals Limited and changed its name to Lupin Limited in 2001. Lupin Limited was founded in 1968 and is headquartered in Mumbai, India.
Stocks similar to LUPIN
- Max Healthcare share price
- Aurobindo Pharma share price
- Glenmark Pharmaceuticals share price
- Cipla share price
- Dr. Reddy's Laboratories share price
- Zydus Lifesciences share price
Compare LUPIN with MAXHEALTH, AUROPHARMA, GLENMARK
Educational information, not investment advice. Data from Yahoo Finance and NSE Indices; prices may be delayed.